Pfizer’s RSV Vaccine Candidate Safe and Effective in Older Adults
Pfizer announced that their new RSV vaccine candidate is more than 85 percent effective in preventing severe lower respiratory tract illness in older adults. They define severe illness as three or more symptoms. The company tested this vaccine candidate in about 37,000 people ages 60 and older and are looking to recruit a total of 40,000. Respiratory syncytial virus, or RSV, is a group of viruses that cause cold-like symptoms, including runny nose, coughing and sneezing. There are a few companies working on RSV vaccine candidates, and Pfizer in particular has announced results from their phase 3 clinical trials of their version called RSVpreF. Read more from The Hill here.